Cannabis-based medicines developer Celadon Pharmaceuticals (LON: CEL) says that the strategic collaboration with Valeos Pharma is contributing to its business. This will enable the acceleration of supply of pharmaceutical grade EU-GMP cannabis active pharmaceutical ingredient products. Valeos Pharma will provide up to three tonnes of annual cultivation capacity, which is equivalent to £8.7m of income/year. The share price jumped 162.5% to 42p.
Shares in fintech Fiinu (LON: BANK) have risen a further 103.9% to 6.625p. following yesterday’s news that it has signed heads of agreement for the first white-label deal for its Plugin Overdraft with a UK bank. It will provide a Banking-as-a-Service platform including Plugin Overdraft and the launch could be in the fourth quarter of 2025.
Cambridge Nutritional Sciences (LON: CNSL) has settled its dispute with the UK DHSC with no admission of liability. The DHSC will not seek reimbursement of pre-production payments for Covid tests and Cambridge Nutritional Sciences will not claim for losses for failure to replace orders. The company will have legal costs of £200,000, but it will also release £2.5m from deferred income as exceptional income. The share price improved 27.1% to 3.75p.
Executive search business Norman Broadbent (LON: NBB) had a stronger fourth quarter in 2024 with net fee income of £2.5m, although it was still slightly lower than the fourth quarter of 2023. Full year net fee income was 13% lower at £9.3m, while underlying EBITDA fell from £900,000 to more than £250,000. Net cash was £100,000 at the end of 2024. Market headwinds are expected to persist in the first half of 2025. The share price rebounded 12.9% to 3.5p.
FALLERS
Deltex Medical Group (LON: DEMG) plans to leave AIM and the share price has halved to 0.04p. This will save £200,000/year. Last year’s revenues from sales of heart monitoring systems improved from £1.8m to £2.1m and cash was £240,000 at the end of 2024. Andy Mears will be replaced as chief executive by Natalie Wettler.
Respiratory treatments developer Synairgen (LON: SNG) has raised £18m from TFG Asset Management. This was not scaled back because the placing and retail offer did not meet the minimum requirement of £2.9m and only £2.2m was offered by investors. That cash has been returned. The cash will fund trial costs and stability testing for the phase 2 INVENT trial for SNG001 in mechanically ventilated patients with confirmed respiratory infections. This should start in a few months. The share price declined 9.43% to 1.9925p.
Waste-to-energy technology developer Powerhouse Energy (LON: PHE) announced mechanical completion of the feedstock testing unit. All equipment is installed, and the commissioning/testing phase will commence. This will showcase the company’s technology. The share price fell 3.57% to 1.08p.
Matthias von Plotho is replacing Jurgen Nowicki as 16.2% shareholder Linde’s representative on the ITM Power (LON: ITM) board. The share price dipped 3.55% to 36.13p.
Ex-dividends
AB Dynamics (LON: ABDP) is paying a final dividend of 5.3p/share and the share price slumped 40p to 1825p.
Character Group (LON: CCT) is paying a final dividend of 11p/share and the share price fell 12p to 258p.
Catalyst Media Group (LON: CMX) is paying a dividend of 4p/share and the share price is unchanged at 80p.
Cerillion (LON: CER) is paying a final dividend of 9.2p/share and the share price slipped 25p to 1570p.
Dewhurst Group (LON: DWHA) is paying a dividend of 11.5p/A share and the A share price is unchanged at 625p.
Dewhurst Group (LON: DWHT) is paying a dividend of 11.5p/share and the ordinary share price is unchanged at 1025p.
Premier Miton (LON: PMI) is paying a final dividend of 3p/share and the share price fell 1.5p to 58.5p.
RWS Holdings (LON: RWS) is paying a final dividend of 10p/share and the share price slipped 12p to 164.8p.